Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET
Company Participants
Lisa Caperelli - VP, Investor Relations
Mike McElhaugh - Interim President, CEO & Director
Karen Sims - Chief Medical Officer
Dave Hastings - CFO
Conference Call Participants
Anthea Li - Jefferies
Roy Buchanan - Citizens JMP
Keay Nakae - Chardan
Brian Skorney - Baird
Operator
Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Third Quarter Financial Results and Corporate Update. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Lisa Caperelli, Vice President of Investor Relations. Please go ahead.
Lisa Caperelli
Thank you, Antoine. Good morning, everyone, and thank you for joining Arbutus' Third Quarter 2024 Financial Results and Corporate Update Call. Joining me today from the Arbutus executive team are Mike McElhaugh, Interim President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Karen Sims, Chief Medical Officer; and Dr. Mike Sofia, Chief Scientific Officer. Mike McElhaugh will provide a corporate update, including an update on our ongoing clinical programs in HBV. Dave will then provide a review of the company's third quarter 2024 financial results. After our prepared remarks, we will open the call for Q&A.
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our annual report on Form 10-K, our quarterly report on Form 10-Q, which will be filed today and from time to time in our other documents filed with the SEC.
With that, I'll turn the call over to Mike McElhaugh. Mike?
Mike McElhaugh
Thank you, Lisa, and good morning, everyone. I appreciate you joining us today.
A few weeks ago, we issued a press release announcing that multiple abstracts highlighting imdusiran data were accepted for presentation at the Liver Meeting 2024, which is the annual meeting held by the American Association for the Study of Liver Diseases. Included in the acceptance are 2 late-breaker poster presentations with the imdusiran data from our ongoing Phase IIa clinical trials IM-PROVE I and IM-PROVE II. Since that meeting kicks off next Friday, November 15, and the data are under embargo, we're not able to provide any updates to those trials at this time. I will, however, review at a high level the data that we presented from those clinical trials earlier this year at the EASL conference. Before doing so, I want to take a minute to discuss why we are focused on a functional cure for patients with chronic hepatitis B.